Forschungsthematik

Aktuelle Forschungsthematik

Themenfeld „Biomarker“

Anhand von Patientenseren sollen tumorspezifische Proteine oder Marker identifiziert werden, die sowohl eine verbesserte Diagnose und Prognose erlauben als auch den Tumorpatienten eine individuelle und effiziente Therapie eröffnen.

Themenfeld „Molekulare Therapie“

In den letzten Jahren ist mit der Idee des „molekularen Targetings“ ein innovatives Konzept vorgelegt worden, mit dem völlig neue Wege in der Tumortherapie beschritten werden können. An Prostata-, Nieren- und Blasen-Karzinomzellen untersuchen wir die biologischen und molekularen Effekte verschiedener Substanzen aus der Familie der Tyrosinkinase-, mTOR- und HDAC-Inhibitoren. Zusätzlich induzieren wir Resistenzen in den Tumorzellen und erarbeiten neue Lösungswege zur Resistenzumgehung.

Themenfeld „Immune Escape“

Das Nierenzellkarzinom (NZK) vermag im Rahmen der hämatogenen Metastasierung Mechanismen zu induzieren, die verhindern, dass zirkulierende immunkompetente Leukozyten zum Tumor vordringen („Tumor-Immune-Escape“). Anhand von NZK-Endothel-Leukozyten-Kokulturmodellen möchten wir relevante Signalproteine identifizieren, die für die Initiierung des Tumor-Immune-Escape Mechanismus verantwortlich sind.

Themenfeld „Natursubstanzen“

Natursubstanzen rücken als potentielle Kandidaten im Rahmen einer Tumorbehandlung zunehmend in den Fokus des Interesses. Unsere Arbeitsgruppe beschäftigt sich mit der Erforschung der Wirksamkeit und Nicht-Wirksamkeit sowie des möglichen klinischen Nutzens von Naturstoffen. Ziel ist es, Patienten und Kliniker über Pro und Kontra verschiedener Phytopharmaka aufzuklären.

Publikationen des Labors seit 2015:

2020:

Justin S, Rutz J, Maxeiner S, Chun FK, Juengel E, Blaheta RA. Bladder Cancer Metastasis Induced by Chronic Everolimus Application Can Be Counteracted by Sulforaphane In Vitro. Int J Mol Sci. 2020 Aug 4;21(15):5582. doi:10.3390/ijms21155582. PMID: 32759798; PMCID: PMC7432076.

 

Zingue S, Maxeiner S, Rutz J, Ndinteh DT, Chun FK, Fohouo FT, Njamen D, Blaheta RA. Ethanol-extracted Cameroonian propolis: Antiproliferative effects and potential mechanism of action in prostate cancer. Andrologia. 2020 Jun 23:e13698. doi: 10.1111/and.13698. Epub ahead of print. PMID: 32573810.

 

Justin S, Rutz J, Maxeiner S, Chun FK, Juengel E, Blaheta RA. Chronic Sulforaphane Administration Inhibits Resistance to the mTOR-Inhibitor Everolimus in Bladder Cancer Cells. Int J Mol Sci. 2020 Jun 4;21(11):4026. doi:10.3390/ijms21114026. PMID: 32512849; PMCID: PMC7312500.

 

Rutz J, Janicova A, Woidacki K, Chun FK, Blaheta RA, Relja B. Curcumin-A Viable Agent for Better Bladder Cancer Treatment. Int J Mol Sci. 2020 May 26;21(11):3761. doi: 10.3390/ijms21113761. PMID: 32466578; PMCID: PMC7312715.

 

Rutz J, Maxeiner S, Justin S, Bachmeier B, Bernd A, Kippenberger S, Zöller N, Chun FK, Blaheta RA. Low Dosed Curcumin Combined with Visible Light Exposure Inhibits Renal Cell Carcinoma Metastatic Behavior In Vitro. Cancers (Basel). 2020 Jan 28;12(2):302. doi: 10.3390/cancers12020302. PMID: 32012894; PMCID: PMC7072295.

 

Mani J, Fleger J, Rutz J, Maxeiner S, Bernd A, Kippenberger S, Zöller N, Chun FK, Relja B, Juengel E, Blaheta RA. Curcumin combined with exposure to visible light blocks bladder cancer cell adhesion and migration by an integrin dependent mechanism. Eur Rev Med Pharmacol Sci. 2019 Dec;23(23):10564-10574. doi:10.26355/eurrev_201912_19698. PMID: 31841214.

 

Zingue S, Gbaweng Yaya AJ, Michel T, Ndinteh DT, Rutz J, Auberon F, Maxeiner S, Chun FK, Tchinda AT, Njamen D, Blaheta RA. Bioguided identification of daucosterol, a compound that contributes to the cytotoxicity effects of Crateva adansonii DC (capparaceae) to prostate cancer cells. J Ethnopharmacol. 2020 Jan 30;247:112251. doi: 10.1016/j.jep.2019.112251. Epub 2019 Sep 24. PMID: 31560992.

 

Mani J, Neuschäfer J, Resch C, Rutz J, Maxeiner S, Roos F, Chun FK, Juengel E, Blaheta RA. Amygdalin Modulates Prostate Cancer Cell Adhesion and Migration In Vitro. Nutr Cancer. 2020;72(3):528-537. doi: 10.1080/01635581.2019.1637442. Epub 2019 Jul 12. PMID: 31298931.

 

2019:

Juengel E, Natsheh I, Najafi R, Rutz J, Tsaur I, Haferkamp A, Chun FK, Blaheta RA. Mechanisms behind Temsirolimus Resistance Causing Reactivated Growth and Invasive Behavior of Bladder Cancer Cells In Vitro. Cancers (Basel). 2019 Jun 4;11(6):777. doi: 10.3390/cancers11060777. PMID: 31167517; PMCID:PMC6627393.

 

Makarević J, Rutz J, Juengel E, Maxeiner S, Tsaur I, Chun FK, Bereiter-Hahn J, Blaheta RA. Influence of the HDAC Inhibitor Valproic Acid on the Growth and Proliferation of Temsirolimus-Resistant Prostate Cancer Cells In Vitro. Cancers (Basel). 2019 Apr 19;11(4):566. doi: 10.3390/cancers11040566. PMID: 31010254; PMCID: PMC6520872.

 

Tsaur I, Hüsch T, Jüngel E, Schneider F, Schneider M, Haferkamp A, Thomas C, Lieb V, Wach S, Taubert H, Chun FK, Blaheta RA. sE-cadherin is upregulated in serum of patients with renal cell carcinoma and promotes tumor cell dissemination in vitro. Urol Oncol. 2019 Jun;37(6):355.e1-355.e9. doi: 10.1016/j.urolonc.2019.03.001. Epub 2019 Apr 18. PMID: 31005422.

 

Rutz J, Maxeiner S, Juengel E, Bernd A, Kippenberger S, Zöller N, Chun FK, Blaheta RA. Growth and Proliferation of Renal Cell Carcinoma Cells Is Blocked by Low Curcumin Concentrations Combined with Visible Light Irradiation. Int J Mol Sci. 2019 Mar 22;20(6):1464. doi: 10.3390/ijms20061464. PMID: 30909499; PMCID: PMC6471746.

 

Mey L, Jung M, Roos F, Blaheta R, Hegele A, Kinscherf R, Urbschat A. NOD1 and NOD2 of the innate immune system is differently expressed in human clear cell renal cell carcinoma, corresponding healthy renal tissue, its vasculature and primary isolated renal tubular epithelial cells. J Cancer Res Clin Oncol. 2019 Jun;145(6):1405-1416. doi: 10.1007/s00432-019-02901-7. Epub 2019 Mar 22. PMID: 30903318.

 

Roos F, Binder K, Rutz J, Maxeiner S, Bernd A, Kippenberger S, Zöller N, Chun FK, Juengel E, Blaheta RA. The Antitumor Effect of Curcumin in Urothelial Cancer Cells Is Enhanced by Light Exposure In Vitro. Evid Based Complement Alternat Med. 2019 Mar 11;2019:6374940. doi: 10.1155/2019/6374940. PMID: 30984278; PMCID: PMC6432698.

 

Mani J, Rutz J, Maxeiner S, Juengel E, Bon D, Roos F, Chun FK, Blaheta RA. Cyanide and lactate levels in patients during chronic oral amygdalin intake followed by intravenous amygdalin administration. Complement Ther Med. 2019 Apr;43:295-299. doi: 10.1016/j.ctim.2019.03.002. Epub 2019 Mar 6. PMID: 30935547.

 

2018:

Rutz J, Juengel E, Euler S, Maxeiner S, Justin S, Roos F, Chun FK, Blaheta RA. Chronic Sulforaphane Application Does Not Induce Resistance in Renal Cell Carcinoma Cells. Anticancer Res. 2018 Nov;38(11):6201-6207. doi: 10.21873/anticanres.12974. PMID: 30396938.

 

Makarević J, Rutz J, Juengel E, Maxeiner S, Mani J, Vallo S, Tsaur I, Roos F, Chun FK, Blaheta RA. HDAC Inhibition Counteracts Metastatic Re-Activation of Prostate Cancer Cells Induced by Chronic mTOR Suppression. Cells. 2018 Sep 1;7(9):129. doi: 10.3390/cells7090129. PMID: 30200497; PMCID: PMC6162415.

 

Juengel E, Erb HHH, Haferkamp A, Rutz J, Chun FK, Blaheta RA. Relevance of the natural HDAC inhibitor sulforaphane as a chemopreventive agent in urologic tumors. Cancer Lett. 2018 Oct 28;435:121-126. doi: 10.1016/j.canlet.2018.07.017. Epub 2018 Jul 17. PMID: 30026053.

 

Jennewein L, Bartsch G, Gust K, Kvasnicka HM, Haferkamp A, Blaheta R, Mittelbronn M, Harter PN, Mani J. Increased tumor vascularization is associated with the amount of immune competent PD-1 positive cells in testicular germ cell tumors. Oncol Lett. 2018 Jun;15(6):9852-9860. doi: 10.3892/ol.2018.8597. Epub 2018 Apr 27. PMID: 29928359; PMCID: PMC6004709.

 

Engl T, Rutz J, Maxeiner S, Fanguen S, Juengel E, Koschade S, Roos F, Khoder W, Tsaur I, Blaheta RA. Acquired resistance to temsirolimus is associated with integrin α7 driven chemotactic activity of renal cell carcinoma in vitro. Oncotarget. 2018 Apr 10;9(27):18747-18759. doi: 10.18632/oncotarget.24650. PMID: 29721158; PMCID: PMC5922352.

 

2017:

Juengel E, Najafi R, Rutz J, Maxeiner S, Makarevic J, Roos F, Tsaur I, Haferkamp A, Blaheta RA. HDAC inhibition as a treatment concept to combat temsirolimus-resistant bladder cancer cells. Oncotarget. 2017 Nov 6;8(66):110016-110028. doi: 10.18632/oncotarget.22454. PMID: 29299126; PMCID: PMC5746361.

 

Linxweiler J, Körbel C, Müller A, Jüngel E, Blaheta R, Heinzelmann J, Stöckle M, Junker K, Menger MD, Saar M. Experimental imaging in orthotopic renal cell carcinoma xenograft models: comparative evaluation of high-resolution 3D ultrasonography, in-vivo micro-CT and 9.4T MRI. Sci Rep. 2017 Oct 27;7(1):14249. doi: 10.1038/s41598-017-14759-1. PMID: 29079842; PMCID: PMC5660163.

 

Vallo S, Rutz J, Kautsch M, Winkelmann R, Michaelis M, Wezel F, Bartsch G, Haferkamp A, Rothweiler F, Blaheta RA, Cinatl J Jr. Blocking integrin β1 decreases adhesion in chemoresistant urothelial cancer cell lines. Oncol Lett. 2017 Nov;14(5):5513-5518. doi: 10.3892/ol.2017.6883. Epub 2017 Sep 4. PMID: 29113179; PMCID: PMC5661377.

 

Engl T, Rutz J, Maxeiner S, Juengel E, Roos F, Khoder W, Bechstein WO, Nelson K, Tsaur I, Haferkamp A, Blaheta RA. mTOR inhibition reduces growth and adhesion of hepatocellular carcinoma cells in vitro. Mol Med Rep. 2017 Nov;16(5):7064-7071. doi: 10.3892/mmr.2017.7401. Epub 2017 Aug 31. PMID:28901501.

 

Vallo S, Köpp R, Michaelis M, Rothweiler F, Bartsch G, Brandt MP, Gust KM, Wezel F, Blaheta RA, Haferkamp A, Cinatl J Jr. Resistance to nanoparticle albumin-bound paclitaxel is mediated by ABCB1 in urothelial cancer cells. Oncol Lett. 2017 Jun;13(6):4085-4092. doi: 10.3892/ol.2017.5986. Epub 2017 Apr 5. PMID: 28599410; PMCID: PMC5453046.

 

Juengel E, Euler S, Maxeiner S, Rutz J, Justin S, Roos F, Khoder W, Nelson K, Bechstein WO, Blaheta RA. Sulforaphane as an adjunctive to everolimus counteracts everolimus resistance in renal cancer cell lines. Phytomedicine. 2017 Apr 15;27:1-7. doi: 10.1016/j.phymed.2017.01.016. Epub 2017 Jan 31. PMID: 28314474.

 

Blaheta RA, Oertl A, Freisleben HJ, Nelson K, Ackermann H, Haferkamp A, Engl T. Detection of early DJ-stent encrustation by sonographic twinkling-artifacts - a pilot study. Cent European J Urol. 2017;70(1):107-111. doi: 10.5173/ceju.2017.912. Epub 2017 Mar 14. PMID: 28461998; PMCID: PMC5407330.

 

Juengel E, Krueger G, Rutz J, Nelson K, Werner I, Relja B, Seliger B, Fisslthaler B, Fleming I, Tsaur I, Haferkamp A, Blaheta RA. Correction: Renal cell carcinoma alters endothelial receptor expression responsible for leukocyte adhesion. Oncotarget. 2017 Jan 3;8(1):1953-1954. doi: 10.18632/oncotarget.14438. Erratum for: Oncotarget. 2016 Apr 12;7(15):20410-24. PMID: 28131102; PMCID: PMC5352111.

Borgmann H, Woelm J, Nelson K, Gust K, Mager R, Reiter M, Schilling D, Bartsch G, Blaheta R, Haferkamp A, Tsaur I. Strategy of robotic surgeons to exert public influence through Twitter. Int J Med Robot. 2017 Mar;13(1). doi: 10.1002/rcs.1739. Epub 2016 Feb 23. PMID: 26914176.

 

2016:

Juengel E, Maxeiner S, Rutz J, Justin S, Roos F, Khoder W, Tsaur I, Nelson K, Bechstein WO, Haferkamp A, Blaheta RA. Sulforaphane inhibits proliferation and invasive activity of everolimus-resistant kidney cancer cells in vitro. Oncotarget. 2016 Dec 20;7(51):85208-85219. doi: 10.18632/oncotarget.13421. PMID: 27863441; PMCID: PMC5356730.

 

Vallo S, Michaelis M, Gust KM, Black PC, Rothweiler F, Kvasnicka HM, Blaheta RA, Brandt MP, Wezel F, Haferkamp A, Cinatl J Jr. Dasatinib enhances tumor growth in gemcitabine-resistant orthotopic bladder cancer xenografts. BMC ResNotes. 2016 Sep 27;9(1):454. doi: 10.1186/s13104-016-2256-3. PMID: 27677700; PMCID: PMC5039786.

 

Juengel E, Krueger G, Rutz J, Nelson K, Werner I, Relja B, Seliger B, Fisslthaler B, Fleming I, Tsaur I, Haferkamp A, Blaheta RA. Renal cell carcinoma alters endothelial receptor expression responsible for leukocyte adhesion. Oncotarget. 2016 Apr 12;7(15):20410-24. doi: 10.18632/oncotarget.7804. Erratum in: Oncotarget. 2017 Jan 3;8(1):1953-1954. PMID: 26943029; PMCID: PMC4991464.

 

Blaheta RA, Nelson K, Haferkamp A, Juengel E. Amygdalin, quackery or cure? Phytomedicine. 2016 Apr 15;23(4):367-76. doi: 10.1016/j.phymed.2016.02.004. Epub 2016 Feb 17. PMID: 27002407.

 

Makarević J, Tsaur I, Juengel E, Borgmann H, Nelson K, Thomas C, Bartsch G, Haferkamp A, Blaheta RA. Amygdalin delays cell cycle progression and blocks growth of prostate cancer cells in vitro. Life Sci. 2016 Feb 15;147:137-42. doi: 10.1016/j.lfs.2016.01.039. Epub 2016 Jan 29. PMID: 26827990.

 

Juengel E, Afschar M, Makarević J, Rutz J, Tsaur I, Mani J, Nelson K, Haferkamp A, Blaheta RA. Amygdalin blocks the in vitro adhesion and invasion of renal cell carcinoma cells by an integrin-dependent mechanism. Int J Mol Med. 2016 Mar;37(3):843-50. doi: 10.3892/ijmm.2016.2454. Epub 2016 Jan 8. PMID: 26781971.

 

Tsaur I, Thurn K, Juengel E, Oppermann E, Nelson K, Thomas C, Bartsch G, Oremek GM, Haferkamp A, Rubenwolf P, Blaheta RA. Evaluation of TKTL1 as a biomarker in serum of prostate cancer patients. Cent European J Urol. 2016;69(3):247-251. doi:  0.5173/ceju.2016.820. Epub 2016 Jun 30. PMID: 27729989; PMCID: PMC5057049.

 

Bartsch G, Jennewein L, Harter PN, Antonietti P, Blaheta RA, Kvasnicka HM, Kögel D, Haferkamp A, Mittelbronn M, Mani J. Autophagy-associated proteins BAG3 and p62 in testicular cancer. Oncol Rep. 2016 Mar;35(3):1629-35. doi:10.3892/or.2015.4505. Epub 2015 Dec 22. PMID: 26707573.

 

Juengel E, Thomas A, Rutz J, Makarevic J, Tsaur I, Nelson K, Haferkamp A, Blaheta RA. Amygdalin inhibits the growth of renal cell carcinoma cells in vitro. Int J Mol Med. 2016 Feb;37(2):526-32. doi: 10.3892/ijmm.2015.2439. Epub 2015 Dec 21. PMID: 26709398.

 

2015:

Mani J, Juengel E, Arslan I, Bartsch G, Filmann N, Ackermann H, Nelson K, Haferkamp A, Engl T, Blaheta RA. Use of complementary and alternative medicine before and after organ removal due to urologic cancer. Patient Prefer Adherence. 2015 Oct 1;9:1407-12. doi: 10.2147/PPA.S90061. PMID: 26491269; PMCID: PMC4599187.

 

Grimmig T, Matthes N, Hoeland K, Tripathi S, Chandraker A, Grimm M, Moench R, Moll EM, Friess H, Tsaur I, Blaheta RA, Germer CT, Waaga-Gasser AM, Gasser M. TLR7 and TLR8 expression increases tumor cell proliferation and promotes chemoresistance in human pancreatic cancer. Int J Oncol. 2015 Sep;47(3):857-66. doi: 10.3892/ijo.2015.3069. Epub 2015 Jul 2. PMID: 26134824; PMCID: PMC4532221.

 

Mani J, Antonietti P, Rakel S, Blaheta R, Bartsch G, Haferkamp A, Kögel D. Knockdown of BAG3 sensitizes bladder cancer cells to treatment with the BH3 mimetic ABT-737. World J Urol. 2016 Feb;34(2):197-205. doi: 10.1007/s00345-015-1616-2. Epub 2015 Jun 23. PMID: 26100943.

 

Tsaur I, Thurn K, Juengel E, Gust KM, Borgmann H, Mager R, Bartsch G, Oppermann E, Ackermann H, Nelson K, Haferkamp A, Blaheta RA. sE-cadherin serves as a diagnostic and predictive parameter in prostate cancer patients. J Exp Clin Cancer Res. 2015 May 14;34(1):43. doi: 10.1186/s13046-015-0161-6. PMID: 25967040; PMCID: PMC4490684.

 

Mani J, Vallo S, Rakel S, Antonietti P, Gessler F, Blaheta R, Bartsch G, Michaelis M, Cinatl J, Haferkamp A, Kögel D. Chemoresistance is associated with increased cytoprotective autophagy and diminished apoptosis in bladder cancer cells treated with the BH3 mimetic (-)-Gossypol (AT-101). BMC Cancer. 2015 Apr 7;15:224. doi: 10.1186/s12885-015-1239-4. PMID: 25885284; PMCID: PMC4409725.

 

Tsaur I, Hudak L, Makarević J, Juengel E, Mani J, Borgmann H, Gust KM, Schilling D, Bartsch G, Nelson K, Haferkamp A, Blaheta RA. Intensified antineoplastic effect by combining an HDAC-inhibitor, an mTOR-inhibitor and low dosed interferon alpha in prostate cancer cells. J Cell Mol Med. 2015 Aug;19(8):1795-804. doi: 10.1111/jcmm.12583. Epub 2015 Mar 26. PMID: 25808196; PMCID: PMC4549030.

 

Gerber U, Hoß SG, Shteingauz A, Jüngel E, Jakubzig B, Ilan N, Blaheta R, Schlesinger M, Vlodavsky I, Bendas G. Latent heparanase facilitates VLA-4-mediated melanoma cell binding and emerges as a relevant target of heparin in the interference with metastatic progression. Semin Thromb Hemost. 2015 Mar;41(2):244-54. doi: 10.1055/s-0035-1544229. Epub 2015 Feb 15. PMID: 25682080.

 

Mani J, Juengel E, Bartsch G, Filmann N, Ackermann H, Nelson K, Haferkamp A, Engl T, Blaheta RA. Globalization in Urology: A Bibliographical Analysis of Cross-Continent Publication between 2002 and 2012. Urol Int. 2015;95(3):281-7. doi: 10.1159/000438830. Epub 2015 Sep 9. PMID: 26346650.

 

Juengel E, Kim D, Makarević J, Reiter M, Tsaur I, Bartsch G, Haferkamp A, Blaheta RA. Molecular analysis of sunitinib resistant renal cell carcinoma cells after sequential treatment with RAD001 (everolimus) or sorafenib. J Cell Mol Med. 2015 Feb;19(2):430-41. doi: 10.1111/jcmm.12471. Epub 2014 Dec 2. PMID: 25444514; PMCID: PMC4407590.

 

Tsaur I, Noack A, Makarevic J, Oppermann E, Waaga-Gasser AM, Gasser M, Borgmann H, Huesch T, Gust KM, Reiter M, Schilling D, Bartsch G, Haferkamp A, Blaheta RA. CCL2 Chemokine as a Potential Biomarker for Prostate Cancer: A Pilot Study. Cancer Res Treat. 2015 Apr;47(2):306-12. doi: 10.4143/crt.2014.015. Epub 2014 Oct 13. PMID: 25483747; PMCID: PMC4398105.

 

Tsaur I, Rutz J, Makarević J, Juengel E, Gust KM, Borgmann H, Schilling D, Nelson K, Haferkamp A, Bartsch G, Blaheta RA. CCL2 promotes integrin-mediated adhesion of prostate cancer cells in vitro. World J Urol. 2015 Jul;33(7):1051-6. doi: 10.1007/s00345-014-1389-z. Epub 2014 Sep 2. PMID: 25179012.